Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bimatoprost
Drug ID BADD_D00274
Description Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma.[L6877,L6892,L6898,L12069] Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth.[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.[L4894]
Indications and Usage Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.[L6877] Bimatoprost is also indicated to treat eyelash hypotrichosis.[L6910]
Marketing Status approved; investigational
ATC Code S01EE03
DrugBank ID DB00905
KEGG ID D02724
MeSH ID D000069580
PubChem ID 5311027
TTD Drug ID D0Q2XF
NDC Product Code 73309-002; 73212-076; 50383-908; 70069-403; 72266-139; 0781-6206; 42385-030; 54893-0009; 55679-113; 42571-128; 0023-3616; 0023-9652; 62332-511; 65862-802; 70069-401; 24002-0021; 76397-016; 46708-511; 72266-241; 38779-3066; 51552-1618; 50383-912; 0023-3205; 60505-0583; 68083-296; 68083-439; 65129-1206; 72266-140; 12079-1067; 57741-3000; 68083-295; 68180-429; 61556-070; 68245-0004; 71052-276; 73309-022; 73377-230; 82187-1001; 62332-507; 54245-7036; 63190-0290; 65035-130; 65727-025; 82231-102; 70069-402; 40016-005
UNII QXS94885MZ
Synonyms Bimatoprost | Latisse | Lumigan | AGN 192024 | 192024, AGN
Chemical Information
Molecular Formula C25H37NO4
CAS Registry Number 155206-00-1
SMILES CCNC(=O)CCCC=CCC1C(CC(C1C=CC(CCC2=CC=CC=C2)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal sensation in eye06.01.01.0010.002092%-
Accommodation disorder06.02.04.0010.000598%-
Acne23.02.01.0010.001582%-
Alopecia23.02.02.001--
Anxiety19.06.02.002--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.0010.002689%-
Application site irritation12.07.01.003; 08.02.01.0030.001195%-
Application site pain12.07.01.004; 08.02.01.0040.002689%-
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.0050.002689%-
Arrhythmia02.03.02.0010.000562%-
Arthritis15.01.01.001--
Asthenia08.01.01.001---
Asthenopia06.01.01.0020.000686%-
Asthma22.03.01.002; 10.01.03.010---
Basal cell carcinoma23.08.02.001; 16.03.02.0010.000176%-
Bladder pain20.02.02.001---
Blepharal pigmentation23.05.01.009; 06.06.04.0140.009140%-
Blepharitis23.03.04.012; 06.04.04.0010.005642%-
Blepharospasm06.05.01.001; 17.17.02.0010.001793%-
Blindness06.02.10.003; 17.17.01.0030.000264%-
Blindness transient06.02.10.006; 17.17.01.0040.000562%-
Blindness unilateral06.02.10.007; 17.17.01.0160.000439%-
Breast cancer21.05.01.003; 16.10.01.001---
Bronchitis11.01.09.001; 22.07.01.001--
Burning sensation17.02.06.001; 08.01.09.0290.002988%-
Cataract06.06.01.0010.001213%
Cataract subcapsular06.06.01.0020.000176%-
Chalazion06.04.04.002---
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003---
Choroidal detachment12.01.04.006; 06.09.01.0030.000176%-
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene